Dermatologic Manifestations of Kaposi Sarcoma Workup

  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Feb 22, 2012
 

Laboratory Studies

  • Serum glucose levels may reflect an increased incidence of diabetes mellitus in patients with classic Kaposi sarcoma (KS). Ketoacidosis is unusual in these patients.
  • Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 has been claimed as useful in the diagnosis of Kaposi sarcoma.[38]
  • Hemogram in nonimmunosuppressed patients with Kaposi sarcoma tends to be within normal limits, but occasionally, monocytosis or eosinophilia has been noted. Eosinophilia is seen especially in African patients and patients who are homosexual, in whom parasitosis may be common.
  • In KS-AIDS, cytopenia of 1 or more cell lines is frequent.
  • Anemia, if present, may result from gastrointestinal bleeding or may be associated with an autoimmune hemolytic anemia or a hematologic malignancy.
  • Assays for HHV-8 have been challenging. At present, no universally accepted method exists.
  • Polymerase chain reaction often is used but may have false-positive results because of its high susceptibility to contamination.
  • Methods based on both lytic and latent-phase viral antigens remain promising.
Next

Imaging Studies

  • Computed tomography (CT) may be valuable, especially abdominal CT scans in patients with AIDS.[39] In AIDS-related Kaposi sarcoma, early lymphatic and hepatosplenic involvement may be evident. Consider CT-directed fine needle aspiration to provide tissue confirmation, since lymphomas and atypical mycobacterial and other infections may appear similar.
  • Consider endoscopic and conventional radiographic studies; however, these modalities may miss gastrointestinal Kaposi sarcoma, while selective angiography may demonstrate Kaposi sarcoma.
  • Radionucleotide scans may be useful in demonstrating visceral Kaposi sarcoma and associated lymphoma.
  • With lung nodules, the distinction between Kaposi sarcoma, lymphoma, and/or opportunistic infection may be challenging.
  • In both adults and children with pulmonary Kaposi sarcoma, chest radiography shows perihilar and lower zone involvement.[40] Pleural effusions appear to be more common on radiographs in children.
Previous
Next

Other Tests

Evaluation for Kaposi sarcoma should include a complete physical examination and a biopsy of suspected lesions including lymph nodes. CT scan used to guide a fine needle for tissue specimens appears promising.

The cell of origin in Kaposi sarcoma remains a subject of dispute, although the following tests may be useful:

  • Ultrastructural and immunohistochemical testing favor the endothelial cell.
  • The presence of factor VIII–related antigen, human leukocyte antigen DR (HLA-DR), von Willebrand factor, and the lectin Ulex europaeus I (which all are markers for endothelial cells) is highly suggestive.
  • Reactivity with 2 monoclonal antibodies (EN4 and PAL E) implies that Kaposi sarcoma is derived from endothelium of lymphatic origin; however, Kaposi sarcoma spindle cells express CD34 antigen, a glycoprotein expressed by endothelial cells of small blood vessels (but not those of lymphatic origin).
Previous
Next

Histologic Findings

Kaposi sarcoma (KS) tends to demonstrate increased spindle cells with vascular slits and vascular structures with a predominance of endothelial cells. Extravasated erythrocytes and hemosiderin-laden macrophages often are evident. Some spindle cells may show nuclear pleomorphism. Early Kaposi sarcoma may resemble granulation tissue with a diffuse chronic inflammatory infiltrate and capillaries dilated and increased in number. This pattern also is seen in lymph nodes and viscera.

Histopathologic classification is based on relative contribution of spindle cells, fibrosis, and nuclear pleomorphism, sometimes divided into 3 histopathologic forms, which include (1) a mixed form with an equal amount of spindle cells, vascular clefts, and capillaries, (2) a mononuclear type with 1 cell type predominating, and (3) an anaplastic form with cellular pleomorphism and numerous mitotic figures. In 2007, intravascular Kaposi sarcoma was recognized as a morphological variant of Kaposi sarcoma that seems to be unassociated with an increased risk of aggressive behavior.[41]

Cutaneous Kaposi sarcoma probably evolves through the early inflammatory or patch stage, progresses to the nodular stage, and then, to the late proliferative or plaque stage. The authors believe that the glomeruluslike vascular formations in early patch stage Kaposi sarcoma and in some later lesions may reflect the histogenesis of Kaposi sarcoma. The late plaque stage shows diffuse involvement of the dermis, exhibiting the histologic features of the nodular stage. The lesions may resolve, with involution of the vascular components and formation of scar tissue, or, occasionally, they become extremely pleomorphic and invade deeper tissues. Histologic variants have been recently emphasized.[42]

Kaposi sarcoma specimens may be stained for iron and HHV-8.[43] Iron staining of dermal tissue may suggest Kaposi sarcoma. Immunohistochemical stains for HHV-8 should be positive in most typical Kaposi sarcoma. Iron staining and immunohistochemical HHV-8 staining in combination may be reliable markers for Kaposi sarcoma compared with interstitial granuloma annulare.

The lymphadenopathy in Kaposi sarcoma may show marked follicular hyperplasia and hypervascularity, nonspecific inflammation in regional lymph nodes that drain ulcerated Kaposi sarcoma, and lymphomas or actual lymph node Kaposi sarcoma, with or without cutaneous involvement. More than 1 of these processes may be evident in the same node. The authors view localized lymphadenopathic Kaposi sarcoma as a type of localized nodular Kaposi sarcoma. Kaposi sarcoma in nodes shows the typical proliferation of spindle cells separated by slitlike spaces containing red blood cells and is accompanied by marked follicular hyperplasia and plasmacytic infiltration. The earliest changes occur in the subcapsular and trabecular sinuses, with extension into the entire node and, later, the perinodal tissues. Kaposi sarcoma of lymph nodes may be localized or generalized. The lymphocytic, plasmacytic, and immunoblastic proliferation may simulate a lymphoma.

The electron microscopy and immunohistochemical features of Kaposi sarcoma may be important. Staining with CD34, factor VIII–related antigen, the lectin Ulex europaeus I, and HLA-DR antigen may be useful to support or confirm the diagnosis of Kaposi sarcoma. The authors prefer CD34 antigen, which is expressed by Kaposi sarcoma cells, and find it helpful in distinguishing Kaposi sarcoma from pseudo-Kaposi sarcoma (acroangiodermatitis).

See the images below.

Intermediate lesion showing moderately enlarged spIntermediate lesion showing moderately enlarged spindle cells, some of which line poorly formed blood vessels that open into the interstitium with extravasation of erythrocytes. Erythrophagocytosis by these spindle cells is noted in places (hematoxylin and eosin, magnification X80). Early lesion showing increased cellularity of the Early lesion showing increased cellularity of the dermis with slightly enlarged spindle cells of focally fine stellate blood vessels that open at their corners into the interstitium (hematoxylin and eosin, magnification X40). Keloidal Kaposi sarcoma demonstrating features botKeloidal Kaposi sarcoma demonstrating features both of keloids and Kaposi sarcoma (hematoxylin and eosin, magnification X80). Late lesion showing masses of moderately atypical Late lesion showing masses of moderately atypical spindle cells in a haphazard array, some of which line poorly formed blood vessels. Many of the spindle cells show erythrophagocytosis (hematoxylin and eosin, magnification X40). Late lesion showing atypical spindle cells, some oLate lesion showing atypical spindle cells, some of which are lining poorly formed blood vessels, with prominent erythrophagocytosis by the cells (hematoxylin and eosin, magnification X80).
Previous
Next

Staging

Stage the patient's disease and note any extracutaneous involvement. Staging this multicentric disorder has been a challenge.[44]

The AIDS Clinical Trials Group classification by Krown et al[45] in 1989 uses the following 3 categories, although the tumor/immune/system/systemic (TIS) illness grading method has limitations.

  • Tumor (T) - Good or bad risk signs (good when Kaposi sarcoma is confined to skin and/or lymph nodes and/or demonstrates minimal oral disease)
  • Immune system (I) - CD4 cell levels equal to or greater than 150/µL (good risk) versus less than 150/µL (poor risk)
  • Systemic illness (S) - Good or poor risk

Another classification formula developed by Mitsuyasu in 1987[46] divides Kaposi sarcoma into 4 stages.

  • Stage I - Localized nodular Kaposi sarcoma in elderly men in North America and Europe
  • Stage II - Localized, invasive, and aggressive Kaposi sarcoma (mostly seen in Africa)
  • Stage III - Disseminated mucocutaneous Kaposi sarcoma in African children and patients who are homosexual
  • Stage IV - Stage III with visceral involvement

In 1984, the authors originally proposed and currently prefer the following classification system (including new recommended modifications):

  • Stage I represents localized nodular Kaposi sarcoma, with more than 15 cutaneous lesions or involvement restricted to 1 bilateral anatomic site, and few, if any, gut nodules.
  • Stage II includes both exophytic destructive lesions and locally infiltrative cutaneous lesions as locally aggressive Kaposi sarcoma.
  • Stage III (generalized lymphadenopathic Kaposi sarcoma) has widespread lymph node involvement, with or without skin lesions, but with no visceral involvement.
  • Stage IV (disseminated visceral Kaposi sarcoma) has widespread Kaposi sarcoma, usually progressing from Stage II or Stage III, with involvement of multiple visceral organs.

The authors modify each stage as follows:

  • A: Associated opportunistic infection(s) is evident.
  • B: Patient is HIV-I seropositive.
  • C: Cutaneous anergy or other evidence of severe immunodeficiency is present.
Previous
Proceed to Treatment & Management
 
 
Contributor Information and Disclosures
Author

Robert A Schwartz, MD, MPH  Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, University of Medicine and Dentistry of New Jersey-New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

W Clark Lambert, MD, PhD  Professor and Head, Dermatopathology, Departments of Pathology and Dermatology, UMDNJ-New Jersey Medical School

W Clark Lambert, MD, PhD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, American Dermatological Association, American Society of Dermatopathology, International Academy of Pathology, Medical Society of New Jersey, Sigma Xi, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

Abby S Van Voorhees, MD  Assistant Professor, Director of Psoriasis Services and Phototherapy Units, Department of Dermatology, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania

Abby S Van Voorhees, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, National Psoriasis Foundation, Phi Beta Kappa, Sigma Xi, and Women's Dermatologic Society

Disclosure: Amgen Honoraria Consulting; Abbott Honoraria Consulting; Merck Salary Management position; Abbott Honoraria Speaking and teaching; Amgen Honoraria Review panel membership; Centocor Honoraria Consulting; Leo Consulting; Merck None Other

Michael J Wells, MD  Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association

Disclosure: Nothing to disclose.

Christen M Mowad, MD  Associate Professor, Department of Dermatology, Geisinger Medical Center

Christen M Mowad, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Joel M Gelfand, MD, MSCE  Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania

Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology

Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

Dirk M Elston, MD  Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Ronchese F. Kaposi's sarcoma; an overlooked essay of 1882. AMA Arch Derm. May 1958;77(5):542-5. [Medline].

  2. Schiavo AL, Ruocco V, Marino F, Ferraiolo S, Pinto F, Orlando G. Tommaso de Amicis, Augusto Ducrey, Lodovico Tommasi: three Neapolitan stars in the dermatovenereology firmament. Int J Dermatol. Jan 1996;35(1):57-62. [Medline].

  3. Borkovic SP, Schwartz RA. Kaposi's sarcoma presenting in the homosexual man -- a new and striking phenomenon!. Ariz Med. Dec 1981;38(12):902-4. [Medline].

  4. Borkovic SP, Schwartz RA. Kaposi's sarcoma. Am Fam Physician. Oct 1982;26(4):133-7. [Medline].

  5. Friedman-Kien AE. Disseminated Kaposi's sarcoma syndrome in young homosexual men. J Am Acad Dermatol. Oct 1981;5(4):468-71. [Medline].

  6. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. Dec 10 1981;305(24):1425-31. [Medline].

  7. Allan AE, Shoji T, Li N, Burlage A, Davis B, Bhawan J. Two cases of Kaposi's sarcoma mimicking Stewart-Treves syndrome found to be human herpesvirus-8 positive. Am J Dermatopathol. Oct 2001;23(5):431-6. [Medline].

  8. Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol. Aug 2008;59(2):179-206; quiz 207-8. [Medline].

  9. Ruocco V, Ruocco E, Schwartz RA, Janniger CK. Kaposi sarcoma and quinine: A potentially overlooked triggering factor in millions of Africans. J Am Acad Dermatol. Feb 2011;64(2):434-6. [Medline].

  10. Ruocco V, Ruocco E, Schwartz RA, Janniger CK. Kaposi's sarcoma and quinine: a potentially overlooked triggering factor in millions of Africans. J Am Acad Dermatol. 2010;in press.

  11. Biggar RJ, Whitby D, Marshall V, Linhares AC, Black F. Human herpesvirus 8 in Brazilian Amerindians: a hyperendemic population with a new subtype. J Infect Dis. May 2000;181(5):1562-8. [Medline].

  12. Ascoli V, Zambon P, Manno D, et al. Variability in the incidence of classic Kaposi's sarcoma in the Veneto region, Northern Italy. Tumori. Mar-Apr 2003;89(2):122-4. [Medline].

  13. Santarelli R, De Marco R, Masala MV, et al. Direct correlation between human herpesvirus-8 seroprevalence and classic Kaposi's sarcoma incidence in Northern Sardinia. J Med Virol. Oct 2001;65(2):368-72. [Medline].

  14. Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin?. Annu Rev Microbiol. 2003;57:609-39. [Medline].

  15. Tornesello ML, Biryahwaho B, Downing R, et al. Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era. Virology. Mar 15 2010;398(2):280-9. [Medline].

  16. Serwin AB, Mysliwiec H, Wilder N, Schwartz RA, Chodynicka B. Three cases of classic Kaposi's sarcoma with different subtypes of Kaposi's sarcoma-associated herpesvirus. Int J Dermatol. Jul 2006;45(7):843-6. [Medline].

  17. Cassar O, Blondot ML, Mohanna S, et al. Human herpesvirus 8 genotype E in patients with Kaposi sarcoma, Peru. Emerg Infect Dis. Sep 2010;16(9):1459-62. [Medline].

  18. Ramos da Silva S, Ferraz da Silva AP, Bacchi MM, Bacchi CE, Elgui de Oliveira D. KSHV genotypes A and C are more frequent in Kaposi sarcoma lesions from Brazilian patients with and without HIV infection, respectively. Cancer Lett. Feb 1 2011;301(1):85-94. [Medline].

  19. Dupin N, Grange PA. Looking for the target cell of Kaposi's sarcoma-associated herpesvirus. J Invest Dermatol. Mar 2006;126(3):545-7. [Medline].

  20. Gantt S, Kakuru A, Wald A, et al. Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatr Blood Cancer. May 2010;54(5):670-4. [Medline].

  21. Onunu AN, Okoduwa C, Eze EU, Adeyekun AA, Kubeyinje EP, Schwartz RA. Kaposi's sarcoma in Nigeria. Int J Dermatol. Mar 2007;46(3):264-7. [Medline].

  22. Polesel J, Franceschi S, Suligoi B, Crocetti E, Falcini F, Guzzinati S, et al. Cancer incidence in people with AIDS in Italy. Int J Cancer. Jan 4 2010;[Medline].

  23. Stratigos JD, Potouridou I, Katoulis AC, et al. Classic Kaposi's sarcoma in Greece: a clinico-epidemiological profile. Int J Dermatol. Oct 1997;36(10):735-40. [Medline].

  24. Barco D, Alegre M, Alomar A. [Classic kaposi sarcoma associated with lymphedema following arterial catheterization]. Actas Dermosifiliogr. Oct 2008;99(8):665-7. [Medline].

  25. Ruocco V, Schwartz RA, Ruocco E. Lymphedema: an immunologically vulnerable site for development of neoplasms. J Am Acad Dermatol. Jul 2002;47(1):124-7. [Medline].

  26. Atzori L, Fadda D, Ferreli C, et al. Classic Kaposi's sarcoma in southern Sardinia, Italy. Br J Cancer. Oct 4 2004;91(7):1261-2. [Medline].

  27. Qunibi W, Al-Furayh O, Almeshari K, et al. Serologic association of human herpesvirus eight with posttransplant Kaposi's sarcoma in Saudi Arabia. Transplantation. Feb 27 1998;65(4):583-5. [Medline].

  28. Phipps W, Ssewankambo F, Nguyen H, et al. Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda. PLoS One. Nov 12 2010;5(11):e13936. [Medline]. [Full Text].

  29. Wolf R, Brenner S, Ruocco V, Filioli FG. Isotopic response. Int J Dermatol. May 1995;34(5):341-8. [Medline].

  30. Micali G, Nasca MR, De Pasquale R, Innocenzi D. Primary classic Kaposi's sarcoma of the penis: report of a case and review. J Eur Acad Dermatol Venereol. May 2003;17(3):320-3. [Medline].

  31. Schwartz RA, Cohen JB, Watson RA, et al. Penile Kaposi's sarcoma preceded by chronic penile lymphoedema. Br J Dermatol. Jan 2000;142(1):153-6. [Medline].

  32. Elsaie ML, Shehu YM, Sani MU, Borodo MM, Mohammed AZ. Disseminated vitiligo developing around Kaposi sarcoma nodules in an AIDS patient. Cutis. Nov 2011;88(5):237-9. [Medline].

  33. Aïm F, Rosier L, Dumontier C. Isolated Kaposi sarcoma of the finger pulp in an AIDS patient. Orthop Traumatol Surg Res. Feb 2012;98(1):126-8. [Medline].

  34. Silapunt S, Jordon RE, Piao Y, Tsai KY. Kaposi sarcoma presenting as a cutaneous horn. J Am Acad Dermatol. Feb 2011;64(2):447-8. [Medline].

  35. Elliott AM, Luzze H, Quigley MA, et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis. Sep 1 2004;190(5):869-78. [Medline].

  36. Vanousova D, Jilich D, Machala L, et al. [Diagnostic pitfalls of HIV-associated Kaposi's sarcoma]. Klin Onkol. 2010;23(5):285-92. [Medline].

  37. Straka L, Adamicová K. [Reactive angioendotheliomatosis--a rare disease mimicking Kaposi sarcoma: a case report]. Cesk Patol. Oct 2004;40(4):162-6. [Medline].

  38. Patel RM, Goldblum JR, Hsi ED. Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma. Mod Pathol. Apr 2004;17(4):456-60. [Medline].

  39. O'Mahony D, Gandjbakche A, Hassan M, Vogel A, Yarchoan R. Imaging techniques for Kaposi's sarcoma. J HIV Ther. Sep 2008;13(3):65-71. [Medline].

  40. Theron S, Andronikou S, Du Plessis J, et al. Pulmonary Kaposi sarcoma in six children. Pediatr Radiol. Dec 2007;37(12):1224-9. [Medline].

  41. Luzar B, Antony F, Ramdial PK, Calonje E. Intravascular Kaposi's sarcoma - a hitherto unrecognized phenomenon. J Cutan Pathol. Nov 2007;34(11):861-4. [Medline].

  42. O'donnell PJ, Pantanowitz L, Grayson W. Unique Histologic Variants of Cutaneous Kaposi Sarcoma. Am J Dermatopathol. Jan 14 2010;[Medline].

  43. Wada DA, Perkins SL, Tripp S, Coffin CM, Florell SR. Human herpesvirus 8 and iron staining are useful in differentiating Kaposi sarcoma from interstitial granuloma annulare. Am J Clin Pathol. Feb 2007;127(2):263-70. [Medline].

  44. Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi's sarcoma: a useful tool for therapeutic choices. Eur J Dermatol. Jan-Feb 2003;13(1):83-6. [Medline].

  45. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. Sep 1989;7(9):1201-7. [Medline].

  46. Mitsuyasu RT. Clinical variants and staging of Kaposi's sarcoma. Semin Oncol. Jun 1987;14(2 Suppl 3):13-8. [Medline].

  47. Brambilla L, Bellinvia M, Tourlaki A, Scoppio B, Gaiani F, Boneschi V. Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol. Nov 25 2009;[Medline].

  48. Fardet L, Stoebner PE, Bachelez H, et al. Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. Cancer. Apr 15 2006;106(8):1785-9. [Medline].

  49. Di Lorenzo G, Di Trolio R, Montesarchio V, et al. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. Cancer. Mar 1 2008;112(5):1147-52. [Medline].

  50. Klein E, Schwartz RA, Laor Y, Milgrom H, Burgess GH, Holtermann OA. Treatment of Kaposi's sarcoma with vinblastine. Cancer. Feb 1980;45(3):427-31. [Medline].

  51. Goiriz R, Rios-Buceta L, De Arriba AG, Aragues M, Garcia-Diez A. Treatment of classic Kaposi's sarcoma with topical imiquimod. Dermatol Surg. Jan 2009;35(1):147-9. [Medline].

  52. Prinz Vavricka BM, Hofbauer GF, Dummer R, French LE, Kempf W. Topical treatment of cutaneous Kaposi sarcoma with imiquimod 5% in renal-transplant recipients: a clinicopathological observation. Clin Exp Dermatol. Feb 2 2012;[Medline].

  53. Koon HB, Fingleton B, Lee JY, et al. Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. J Acquir Immune Defic Syndr. Jan 1 2011;56(1):64-8. [Medline]. [Full Text].

  54. Rubegni P, Sbano P, De Aloe G, Flori ML, Fimiani M. Thalidomide in the treatment of Kaposi's sarcoma. Dermatology. 2007;215(3):240-4. [Medline].

  55. Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol. Dec 2007;57(6):1046-50. [Medline].

  56. Boratynska M, Watorek E, Smolska D, Patrzalek D, Klinger M. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc. Nov 2007;39(9):2736-9. [Medline].

  57. Leder HA, Galor A, Peters GB, Kedhar SR, Dunn JP, Thorne JE. Resolution of conjunctival Kaposi sarcoma after institution of highly active antiretroviral therapy alone. Br J Ophthalmol. Jan 2008;92(1):151. [Medline].

  58. Olweny CL, Borok M, Gudza I, et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer. Feb 10 2005;113(4):632-9. [Medline].

  59. Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer. Aug 15 2010;116(16):3969-77. [Medline].

  60. Cattani P, Capuano M, Graffeo R, et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in kidney transplant recipients. J Clin Microbiol. Feb 2001;39(2):506-8. [Medline].

  61. Frances C, Mouquet C, Marcelin AG, et al. Outcome of kidney transplant recipients with previous human herpesvirus-8 infection. Transplantation. May 15 2000;69(9):1776-9. [Medline].

  62. Khan MY, Khanam H, Koneru B, Schwartz RA. Kaposi's sarcoma in a liver transplant series. J Med. 1999;30(3-4):185-90. [Medline].

  63. Khan MY, Khanman H, Koneru B. Kaposi's sarcoma in a liver transplantation series. J Med. 2000;30:185-90.

  64. Sabeel AI, Qunibi WY, Alfurayh OA, Al-Meshari K. Kaposi's sarcoma in Sudanese renal transplant recipients: a report from a single center. J Nephrol. May-Jun 2003;16(3):412-6. [Medline].

  65. Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM. Paradoxical Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients Treated With Combination Antiretroviral Therapy After AIDS-Defining Opportunistic Infection. Clin Infect Dis. Feb 2012;54(3):424-33. [Medline]. [Full Text].

  66. Pitche PT, Kombate K, Owono F, Tchangai-Walla K. Kaposi's sarcoma in a hospital setting in Lome (Togo): a study of 93 cases. Int J Dermatol. Oct 2007;46 Suppl 1:42-4. [Medline].

  67. Stefan DC, Stones DK, Wainwright L, Newton R. Kaposi sarcoma in South African children. Pediatr Blood Cancer. Mar 2011;56(3):392-6. [Medline].

  68. Stover KR, Molitorisz S, Swiatlo E, Muzny CA. A Fatal Case of Kaposi Sarcoma Due to Immune Reconstitution Inflammatory Syndrome. Am J Med Sci. Jan 6 2012;[Medline].

 
Previous
Next
 
Elderly American man of Armenian origin with characteristic violaceous plaques of the legs, a good example of classic Kaposi sarcoma.
Man who is homosexual and has HIV infection and Kaposi sarcoma.
Man who is homosexual and has HIV infection and Kaposi sarcoma.
Man who is homosexual and has HIV infection and Kaposi sarcoma.
Elderly man of Mediterranean lineage with hyperkeratotic nodule of Kaposi sarcoma on sole of foot.
Man who is homosexual and has HIV infection and Kaposi sarcoma.
Man who is homosexual and has HIV infection and Kaposi sarcoma.
Man who is homosexual and has HIV infection and Kaposi sarcoma.
A 35-year-old man with dome-shaped locally aggressive tumors, an example of exophytic Kaposi sarcoma with cavernous hemangiomalike histology.
Ecchymotic Kaposi sarcoma in a man who is homosexual.
Intermediate lesion showing moderately enlarged spindle cells, some of which line poorly formed blood vessels that open into the interstitium with extravasation of erythrocytes. Erythrophagocytosis by these spindle cells is noted in places (hematoxylin and eosin, magnification X80).
Early lesion showing increased cellularity of the dermis with slightly enlarged spindle cells of focally fine stellate blood vessels that open at their corners into the interstitium (hematoxylin and eosin, magnification X40).
Keloidal Kaposi sarcoma demonstrating features both of keloids and Kaposi sarcoma (hematoxylin and eosin, magnification X80).
Oral Kaposi sarcoma.
Kaposi sarcoma of the leg.
Late lesion showing masses of moderately atypical spindle cells in a haphazard array, some of which line poorly formed blood vessels. Many of the spindle cells show erythrophagocytosis (hematoxylin and eosin, magnification X40).
Late lesion showing atypical spindle cells, some of which are lining poorly formed blood vessels, with prominent erythrophagocytosis by the cells (hematoxylin and eosin, magnification X80).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.